Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

6
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
6
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

1
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
1
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

327
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
327
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

324
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
324
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

236
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
236

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoimmune hepatitis: Current and future therapies.

Hepatology communications·2024
Same author

Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.

Hepatology communications·2024
Same author

The Importance of Making an Accurate Diagnosis for Hepatic Encephalopathy.

Gastroenterology & hepatology·2024
Same author

Hepatocellular Carcinoma and Hepatitis Delta Virus.

Gastroenterology & hepatology·2023
Same author

The Spectrum of Hepatic Critical Care During Pregnancy: A Clinical Review.

Clinical obstetrics and gynecology·2023
Same author

The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents.

Hepatology (Baltimore, Md.)·2022

Related Experiment Video

Updated: Mar 19, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Generic medications for hepatitis C.

Donald M Jensen1, Phoebe Sebhatu1, Nancy S Reau1

  • 1Section of Hepatology, Department of Medicine, RUSH Medical Center, Chicago, IL, USA.

Liver International : Official Journal of the International Association for the Study of the Liver
|June 17, 2016
PubMed
Summary

High-cost hepatitis C medications face access limits. Generic versions offer affordable alternatives, but personal importation raises medical and legal questions.

Keywords:
counterfeitgenerichepatitis Cregulations

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.3K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Related Experiment Videos

Last Updated: Mar 19, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.3K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Area of Science:

  • Hepatology
  • Pharmacoeconomics
  • Pharmaceutical Law

Background:

  • Hepatitis C treatment advancements include highly effective oral agents.
  • High costs of these novel drugs create access barriers in resource-limited healthcare systems.
  • Generic licensure agreements enable lower-cost formulations in some regions.

Purpose of the Study:

  • To review the medical and legal considerations of personal drug importation for hepatitis C treatments.
  • To address the challenges posed by medication access limitations for hepatitis C antivirals.
  • To explore the viability of importing generic hepatitis C drugs.

Main Methods:

  • Literature review of medical and legal aspects of drug importation.
  • Analysis of regulatory requirements for generic drug quality and bioequivalence.
  • Discussion of ethical considerations in patient access to medication.

Main Results:

  • Generic hepatitis C drugs are significantly cheaper than originator products.
  • Personal drug importation is driven by unmet medical needs and cost barriers.
  • Manufacturing and distribution regulations are crucial for ensuring generic drug safety and efficacy.

Conclusions:

  • Personal importation of generic hepatitis C medications presents complex medical and legal issues.
  • Ensuring the quality and bioequivalence of imported generics is paramount.
  • Balancing drug accessibility with regulatory oversight is essential for public health.